Details of the Drug Pharmacogenomic Perturbation Atlas

Irinotecan Drug Info

Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

60838

ChEBI ID

CHEMBL481

CAS Number

CAS 97682-44-5

TTD Drug ID

D07HOB

VARIDT Drug ID

DR00112

INTEDE Drug ID

DR0881

General Information of Drug (ID: DMP6SC2)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.82	0.00e+0	63/73 (86.3%)	CDKN1A;DDB2;SESN1;...
Influenza A	2.45	0.00e+0	156/172 (90.7%)	TNFRSF10B;CXCL8;FAS;...
Epstein-Barr virus infection	2.39	0.00e+0	189/202 (93.56%)	CDKN1A;DDB2;FAS;...
Herpes simplex virus 1 infection	2.36	0.00e+0	165/498 (33.13%)	FAS;TAP1;IRF7;...
Type I diabetes mellitus	2.31	0.00e+0	38/43 (88.37%)	FAS;HLA-B;IL1B;...
Graft-versus-host disease	2.26	0.00e+0	32/42 (76.19%)	FAS;HLA-B;IL1B;...
Measles	2.21	0.00e+0	133/139 (95.68%)	FAS;MX1;IRF7;...
Cytosolic DNA-sensing pathway	2.20	0.00e+0	52/63 (82.54%)	IRF7;IL1B;NFKBIA;...
Viral protein interaction with cytokine and cytokine re...	2.19	0.00e+0	84/100 (84%)	TNFRSF10B;CXCL8;CXCL2;...
Kaposi sarcoma-associated herpesvirus infection	2.17	0.00e+0	172/193 (89.12%)	CDKN1A;CXCL8;FAS;...
Viral myocarditis	2.14	9.45e-4	53/60 (88.33%)	CXADR;HLA-B;HLA-F;...
Hepatitis C	2.12	8.67e-4	139/157 (88.54%)	CDKN1A;FAS;MX1;...
NF-kappa B signaling pathway	2.10	8.00e-4	90/104 (86.54%)	CXCL8;RELB;GADD45A;...
Legionellosis	2.08	7.43e-4	51/57 (89.47%)	CXCL8;CXCL2;IL1B;...
NOD-like receptor signaling pathway	2.05	6.93e-4	145/181 (80.11%)	CXCL8;IRF7;IRF9;...
Autoimmune thyroid disease	2.04	6.50e-4	46/53 (86.79%)	FAS;HLA-B;HLA-F;...
C-type lectin receptor signaling pathway	2.02	6.12e-4	93/104 (89.42%)	RELB;IRF9;MDM2;...
Allograft rejection	2.00	5.78e-4	32/38 (84.21%)	FAS;HLA-B;HLA-F;...
RIG-I-like receptor signaling pathway	2.00	5.47e-4	64/70 (91.43%)	CXCL8;ISG15;IRF7;...
Necroptosis	1.98	1.04e-3	113/159 (71.07%)	TNFRSF10B;FAS;IRF9;...
IL-17 signaling pathway	1.97	9.90e-4	84/94 (89.36%)	CXCL8;CXCL2;IL1B;...
Pertussis	1.93	3.78e-3	64/76 (84.21%)	CXCL8;IL1B;CALML3;...
TNF signaling pathway	1.91	3.62e-3	103/112 (91.96%)	FAS;CXCL2;IL1B;...
Rheumatoid arthritis	1.91	3.47e-3	78/93 (83.87%)	CXCL8;CXCL2;IL1B;...
Oxidative phosphorylation	1.89	3.33e-3	93/133 (69.92%)	NDUFB1;COX5A;COX7A1;...
Toll-like receptor signaling pathway	1.87	4.00e-3	94/104 (90.38%)	CXCL8;IRF7;IL1B;...
Glutathione metabolism	1.85	5.01e-3	43/57 (75.44%)	GSTM3;GPX2;GSS;...
Histidine metabolism	1.85	4.83e-3	16/22 (72.73%)	ALDH2;ALDH9A1;HAL;...
Small cell lung cancer	1.83	5.55e-3	90/92 (97.83%)	CDKN1A;DDB2;GADD45A;...
Apoptosis	1.82	5.70e-3	126/168 (75%)	TNFRSF10B;FAS;GADD45A;...
Oocyte meiosis	-1.75	3.70e-2	90/129 (69.77%)	MAPK1;MAPK14;ADCY9;...
TGF-beta signaling pathway	-1.78	3.36e-2	81/94 (86.17%)	FBN1;SMURF1;AMH;...
PPAR signaling pathway	-1.78	4.03e-2	66/74 (89.19%)	LPL;MMP1;ANGPTL4;...
Progesterone-mediated oocyte maturation	-1.88	1.20e-2	75/100 (75%)	AKT2;RPS6KA6;MAPK9;...
Steroid biosynthesis	-1.88	1.60e-2	19/20 (95%)	FDFT1;MSMO1;CYP51A1;...
GnRH secretion	-1.91	1.92e-2	60/64 (93.75%)	MAPK1;CGA;TRPC4;...
Cortisol synthesis and secretion	-2.08	9.59e-3	58/65 (89.23%)	SCARB1;CACNA1H;AGTR1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H

NL20	CVCL_0461	Homo sapiens	10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HFL1	CVCL_4295	Homo sapiens	10uM	24H

IMR-90	CVCL_0347	Homo sapiens	10uM	24H

WI-38	CVCL_0579	Homo sapiens	10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H